Selected CD19-directed CAR T-cell trials
| Trial registration no. and name . | Lymphoma status . | N, Lymphoma subtypes . | Ongoing? . | ORR, % . | PFS . | DOR,% . | Median follow-up, mo . |
|---|---|---|---|---|---|---|---|
| NCT00924326 | R/r | N = 43 | No | — | EFS: | 3 y DOR: | 42 |
| NCI trial (axi-cel construct)9 | DLBCL, 28; low-grade B-NHL, 8; | DLBCL, 15 mo; | DLBCL+PMBL, 48; | ||||
| CLL, 7 | Low grade-B NHL, 55 mo; | Low-grade B-NHL, 63; | |||||
| CLL, 40.5 mo | CLL, 50 | ||||||
| NCT02030834 | No curative treatment options, <2-y life expectancy | N = 38 | No | DLBCL, 50; | DLBCL, 5.8 mo; | 49 mo DOR: | 49 |
| Penn trial (tisa-cel construct)8,23 | DLBCL, 24; | FL, 79 | FL, 32.4 mo | DLBCL, 60; | |||
| 14 FL, 14 | FL, 60 | ||||||
| NCT02601313 | R/r after BTKi, chemotherapy, and anti-CD20 antibody | N = 60 | No | 85 | 61% | Not reached | 12.3 |
| ZUMA-224 | MCL (primary analysis) | ||||||
| NCT03105336 | R/r after 2 therapies, including anti-CD20 and alkylating agent | N = 94 | Yes | 94 | — | — | — |
| ZUMA-530 | FL, 80; | ||||||
| MZL, 14 | |||||||
| NCT03331198 | R/r after 3 therapies if standard risk; r/r after 2 therapies if high risk; all received prior ibrutinib | N = 23 | Yes | 82 | — | — | — |
| TRANSCEND CLL 00426 | CLL |
| Trial registration no. and name . | Lymphoma status . | N, Lymphoma subtypes . | Ongoing? . | ORR, % . | PFS . | DOR,% . | Median follow-up, mo . |
|---|---|---|---|---|---|---|---|
| NCT00924326 | R/r | N = 43 | No | — | EFS: | 3 y DOR: | 42 |
| NCI trial (axi-cel construct)9 | DLBCL, 28; low-grade B-NHL, 8; | DLBCL, 15 mo; | DLBCL+PMBL, 48; | ||||
| CLL, 7 | Low grade-B NHL, 55 mo; | Low-grade B-NHL, 63; | |||||
| CLL, 40.5 mo | CLL, 50 | ||||||
| NCT02030834 | No curative treatment options, <2-y life expectancy | N = 38 | No | DLBCL, 50; | DLBCL, 5.8 mo; | 49 mo DOR: | 49 |
| Penn trial (tisa-cel construct)8,23 | DLBCL, 24; | FL, 79 | FL, 32.4 mo | DLBCL, 60; | |||
| 14 FL, 14 | FL, 60 | ||||||
| NCT02601313 | R/r after BTKi, chemotherapy, and anti-CD20 antibody | N = 60 | No | 85 | 61% | Not reached | 12.3 |
| ZUMA-224 | MCL (primary analysis) | ||||||
| NCT03105336 | R/r after 2 therapies, including anti-CD20 and alkylating agent | N = 94 | Yes | 94 | — | — | — |
| ZUMA-530 | FL, 80; | ||||||
| MZL, 14 | |||||||
| NCT03331198 | R/r after 3 therapies if standard risk; r/r after 2 therapies if high risk; all received prior ibrutinib | N = 23 | Yes | 82 | — | — | — |
| TRANSCEND CLL 00426 | CLL |
BTKi, BTK inhibitor; r/r, relapsed/refractory.